Economic costs incurred by the patients with multiple sclerosis at different levels of the disease: a cross-sectional study in Northwest Iran

Table 2 Status of receiving medical care by pwms related to direct medical costs

Service type	Category	pwmsuse of resources		Frequency of use
Service type	Category	Number of patients	Percentage (rate)	Mean	SD^a
Visit	Specialist visit	294	98.00	7.11	3.77
Diagnosis	Laboratory	214	71.33	2.02	2.36
	MRI^b	219	73.00	1.01	0.86
	CT Scan^c	20	6.66	0.07	0.26
	Other	20	6.66	0.08	0.34
Rehabilitation	Physical therapy	40	13.33	3.55	13.89
Rehabilitation	Occupational therapy	0	0	0	0
Medicine	Avonex	6	2.00
	Betaferron	68	22.66
	Rebief	4	1.33
	CinnoVex	49	16.33
	ReciGen	12	4.00
	Diphosel (Dimethyl fumarate)	65	21.66
	Other MS drugs	67	22.33
	Supplements	79	26.33
Hospitalization	First time	126	42.00	2.94	5.62
	Second time	43	14.33	0.50	1.61
	Third time	3	1.00	0.03	0.28
Other	Informal paid	14	4.66	0.05	0.34
	Complementary/alternative therapies	8	2.66	0.08	0.37
	Home care (medical)	5	1.66	0.15	0.42

ISSN: 1471-2377